SkyOak Wealth LLC Buys Shares of 833 Medpace Holdings, Inc. (NASDAQ:MEDP)

SkyOak Wealth LLC purchased a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 833 shares of the company's stock, valued at approximately $277,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. State Street Corp lifted its position in Medpace by 7.2% in the third quarter. State Street Corp now owns 752,957 shares of the company's stock worth $251,337,000 after purchasing an additional 50,312 shares during the period. Geode Capital Management LLC boosted its position in shares of Medpace by 7.6% during the 3rd quarter. Geode Capital Management LLC now owns 628,054 shares of the company's stock valued at $209,885,000 after acquiring an additional 44,371 shares in the last quarter. Wellington Management Group LLP increased its stake in Medpace by 36.0% in the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company's stock valued at $138,612,000 after acquiring an additional 109,886 shares during the period. American Capital Management Inc. increased its stake in Medpace by 2.6% in the third quarter. American Capital Management Inc. now owns 380,646 shares of the company's stock valued at $127,060,000 after acquiring an additional 9,592 shares during the period. Finally, FMR LLC lifted its stake in Medpace by 11.8% during the third quarter. FMR LLC now owns 231,019 shares of the company's stock worth $77,114,000 after purchasing an additional 24,362 shares during the period. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on MEDP shares. Redburn Atlantic initiated coverage on Medpace in a research note on Monday, October 14th. They issued a "buy" rating and a $404.00 price objective on the stock. Truist Financial lowered their price target on Medpace from $415.00 to $397.00 and set a "hold" rating on the stock in a research report on Monday, October 14th. TD Cowen reduced their target price on shares of Medpace from $413.00 to $372.00 and set a "buy" rating on the stock in a research note on Wednesday, October 23rd. Robert W. Baird upped their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a "neutral" rating in a report on Monday, January 27th. Finally, William Blair reissued an "outperform" rating on shares of Medpace in a report on Tuesday, October 22nd. Seven investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $381.44.

Medpace Trading Up 2.4 %

Shares of MEDP traded up $8.17 during mid-day trading on Wednesday, hitting $355.15. 291,237 shares of the company traded hands, compared to its average volume of 215,371. The stock has a market capitalization of $11.04 billion, a price-to-earnings ratio of 31.10, a PEG ratio of 1.79 and a beta of 1.36. The business has a 50-day moving average of $342.85 and a 200 day moving average of $350.27. Medpace Holdings, Inc. has a one year low of $293.37 and a one year high of $459.77.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.